Mizuho Defends Merck (MRK) on Weakness Related to Pfizer's Antiviral Drug
Tweet Send to a Friend
Mizuho Securities analyst Mara Goldstein defended Merck (NYSE: MRK) following positive news on Pfizer's (NYSE: PFE) oral COVID-19 antiviral drug ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
